Ray Co

Ray Co Debt/EBITDA

The Total Debt to EBITDA Ratio of Ray Co (228670.KQ) as of Oct 28, 2026 is -0.07. In the previous year, Total Debt to EBITDA Ratio was -1.92 — a change of -96.42% (higher).

Debt/EBITDA

-0.07

YoY

-96.42%

Last updated:

Total Debt to EBITDA Ratio of Ray Co is 2025 -0.07 . Total Debt to EBITDA Ratio of Ray Co was 2024 -1.92 . It decreases by -96.42% higher compared to the previous year.

The Ray Co Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2018
0.54 KRW
Jan 1, 2019
0.21 KRW
Jan 1, 2020
1.40 KRW
Jan 1, 2021
17.05 KRW
Jan 1, 2022
2.53 KRW
Jan 1, 2023
2.69 KRW
Jan 1, 2024
-1.92 KRW
Jan 1, 2025
-0.07 KRW
The Ray Co Debt/EBITDA history
YEARDebt/EBITDAYoY
-0.07-96.42%
-1.92-171.29%
2.69+6.49%
2.53-85.19%
17.05+1,120.85%
1.40+555.79%
0.21-60.83%
0.54-75.71%
2.24-35.50%
3.47—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ray Co Stock analysis

What does Ray Co do? Ray Co., Ltd. generates revenue through the manufacturing and sale of advanced technology medical devices, focusing on digital diagnostic systems and digital therapy solutions. The company produces dental radiography equipment such as x-ray systems and cone beam computed tomography (CBCT) systems, alongside 3D scanning, dental computer aided design (CAD), and 3D printers for prosthodontics, orthodontics, and implant surgery. Domestic and overseas markets purchase these products, with the company operating through subsidiaries to distribute its offerings globally. Digital diagnostic systems like dental radiography equipment and CBCT systems are sold to healthcare providers and dental clinics, while digital therapy solutions including 3D scanning and CAD systems target dental laboratories and surgical centers. The firm's product portfolio serves both domestic and international clients, leveraging its subsidiaries for global distribution channels. Ray Co., Ltd. emphasizes advanced technology in its medical device offerings, with digital therapy solutions such as 3D printers and CAD systems being key revenue drivers. The company's focus on dental-specific applications ensures targeted sales to specialized healthcare segments, including prosthodontics, orthodontics, and implant surgery practices. Ray Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ray Co stock

Total Debt to EBITDA Ratio of Ray Co is -0.07 in 2025.

Total Debt to EBITDA Ratio of Ray Co changed from -1.92 to -0.07, representing a -96.42% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Ray Co since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Ray Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Ray Co

All Key Metrics — Ray Co